Risk Mitigation in Direct-to-Patient Clinical Trials
The benefits of direct-to-patient supply to mitigate risk in decentralized studies.
The benefits of direct-to-patient supply to mitigate risk in decentralized studies.
The reasons behind implementing a multi-segment Phase 2 study and implications on kit design.
Proactive Clinical Supply Planning-Early to Late Phase
Management of advanced supply chain CMC collaborators and CDMO partners.
The importance of project management, and key elements to consider to help keep trials on time and budget.
Explore key aspects of Japan’s regulatory environment to consider when developing a clinical supply plan and associated timelines.